1 – 7 of 7
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Rationale and design of the AFFIRM-AHF trial : a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure
(
- Contribution to journal › Article
- 2015
-
Mark
The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study
(
- Contribution to journal › Article
- 2013
-
Mark
The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study
(
- Contribution to journal › Article
-
Mark
Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial
(
- Contribution to journal › Article
- 2012
-
Mark
Levosimendan: Molecular mechanisms and clinical implications Consensus of experts on the mechanisms of action of levosimendan
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Rationale and design of Ferinject((R)) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia
(
- Contribution to journal › Article
-
Mark
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency.
(
- Contribution to journal › Article